



## **Vilanterol**

Catalog No: tcsc1680

Available Sizes
Size: 5mg
Size: 10mg
Size: 50mg
Size: 100mg
Specifications
<b>CAS No:</b> 503068-34-6
Formula: C <sub>24</sub> H <sub>33</sub> Cl <sub>2</sub> NO <sub>5</sub>
Pathway: GPCR/G Protein
Target: Adrenergic Receptor
Purity / Grade: >98%
Solubility: 10 mM in DMSO
Alternative Names: GW642444X;GW642444
Observed Molecular Weight: 486.43





## **Product Description**

Vilanterol is a long-acting  $\beta_2$ -adrenoceptor ( $\beta_2$ -AR) agonist with 24 h activity. The **pEC**<sub>50</sub>s for  $\beta_2$ -AR, $\beta_1$ -AR and  $\beta_3$ -AR is 10.37±0.05, 6.98±0.03 and 7.36±0.03, respectively.

IC50 & Target: pEC50: 10.37  $\pm$  0.05 ( $\beta_2$ -adrenoceptor), 6.98  $\pm$  0.03 ( $\beta_1$ -adrenoceptor), 7.36  $\pm$  0.03 ( $\beta_3$ -adrenoceptor) $^{[1]}$ 

In Vitro: The selectivity of Vilanterol for  $\beta_2$ -AR over the other  $\beta$ -AR receptor subtypes ( $\beta_2$  and  $\beta_3$ ) is established by testing the ability of Vilanterol to elicit concentration-dependent increases in cAMP in CHO cells expressing human  $\beta_1$ -,  $\beta_2$ -, and  $\beta_3$ -AR. Vilanterol is demonstrated to be highly selective for the  $\beta_2$ -AR with at least a 1000-fold selectivity over both  $\beta_2$ - and  $\beta_3$ -AR subtypes. This analysis results in a low-affinity pK $_D$  for [ $^3$ H]Vilanterol of 9.44±0.07 (n=4) in the presence Gpp(NH)p and a high-affinity pK $_D$  of 10.82±0.12 (n=4) and a low-affinity pK $_D$  9.47±0.17 (n=4) in the absence of Gpp(NH)p. In addition, a low-affinity pK $_D$  for [ $^3$ H]Vilanterol of 9.52±0.24 (n=4) in the absence of Gpp(NH)p (37°C) is observed[ $^1$ ]. Vilanterol trifenatate is a novel inhaled long-acting  $\beta_2$ -agonist with inherent 24 h activity in vitro in development as a combination with the inhaled corticosteroid fluticasone furoate for both COPD and asthma[ $^1$ 2]. Vilanterol is a novel long-acting  $\beta_2$ -agonist (LABA) with inherent 24-hour activity for once-daily clinical treatment of chronic obstructive pulmonary disease (COPD) and asthma in combination with the inhaled novel corticosteroid fluticasone furoate, also active for 24 hours[ $^3$ 3].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!